top of page

Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)

HHS-NIH11

Status:

Active

March 18, 2022

Posted:

Deadline: 

May 7, 2025

Funding

Program:

Award Floor:

Ceiling:

Match Required?

No

Eligibility

All

States:

Entity Types:

State governments, County governments, City or township governments, Special district governments, Independent school districts, Public & State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations, Nonprofits (with 501(c)(3) status), Nonprofits (without 501(c)(3) status)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Contact

Email:

Phone:

Source Type:

Federal

The STRIPE program seeks to support pre-clinical research projects utilizing state-of-the-art cancer biology methods and model systems that study how radiopharmaceutical therapy (RPT) agents affect the biology of normal tissue, tumor cells and the tumor microenvironment. Ideally, proposed aims will be designed to test hypotheses on how RPT dynamically impacts cancer biology processes, which can serve as the pre-clinical basis for developing new targeting strategies and approaches. Studies supported by this PAR will ultimately inform the rationale and design of new RPT-based clinical trials.

Tired of searching for grants? Consider a Scouting Report.

bottom of page